Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: A FOCUS study analysis

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3011-3016

  Kiderlen, M ^a   de Glas, N A ^a   Bastiaannet, E ^a   Engels, C C ^a   van de Water, W ^a   de Craen, A J M ^a   Portielje, J E A ^b   van De Velde, C J H ^a   Liefers, G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

Author keywords

Breast cancer; Diabetes; Elderly; Geriatric oncology; Metformin; Observational study

Indexed keywords

ANTINEOPLASTIC AGENT; METFORMIN;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL;

BREAST CANCER; DIABETES; ELDERLY; GERIATRIC ONCOLOGY; METFORMIN; OBSERVATIONAL STUDY;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84888776216     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt367     Document Type: Article

References (27)

1. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007; 8: 1101-1115.
2. Guralnik JM. Assessing the impact of comorbidity in the older population. Ann Epidemiol 1996; 6: 376-380.
3. Braithwaite D, Satariano WA, Sternfeld B et al. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst 2010; 102: 1468-1477.
4. Patnaik JL, Byers T, Diguiseppi C et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011; 103: 1101-1111.
5. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer:a meta-analysis. Int J Cancer 2007; 121: 856-862.
6. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007; 8: 395-408.
7. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565-574.
8. Wolf I, Sadetzki S, Catane R et al. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6: 103-111.
9. Campbell PT, Newton CC, Patel AV et al. Diabetes and cause-specific mortality in a prospective cohort of one million US. adults. Diabetes Care 2012; 35:1835-1844.
10. Currie CJ, Poole CD, Jenkins-Jones S et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
11. Cleveland RJ, North KE, Stevens J et al. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control 2012; 23: 1193-1203.
12. Barone BB, Yeh HC, Snyder CF et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-2764.
13. Nationaal Borstkanker Overleg Nederland. Richtlijn Mammacarcinoom. 2008. Ref Type: Internet Communication.
14. Peairs KS, Barone BB, Snyder CF et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.
15. van de Water W, Markopoulos C, van de Velde CJ et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 2012; 307:590-597.
16. Mell LK, Jeong JH, Nichols MA et al. Predictors of competing mortality in early breast cancer. Cancer 2010; 116: 5365-5373.
17. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multistate models. Stat Med 2007; 26: 2389-2430.
18. Bouma M, Rutten GE, de Grauw WJ et al. Summary of the practice guideline 'Diabetes mellitus type 20 (second revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2006; 150: 2251-2256.
19. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
20. Soares SR, Martinez-Varea A, Hidalgo-Mora JJ et al. Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril 2012; 98: 529-555.
21. Takemura Y, Osuga Y, Yoshino O et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 2007; 92:3213-3218.
22. Schott S, Bierhaus A, Schuetz F et al. Therapeutic effects of metformin in breast cancer: involvement of the immune system? Cancer Immunol Immunother 2011; 60: 1221-1225.
23. Goodwin P. ClinicalTrials.gov-A phase III randomized trial of metformin vs placebo in early stage breast cancer-NCT 01101438. 23-1-2013. Ref Type:Internet Communication.
24. Zulman DM, Sussman JB, Chen X et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783-790.
25. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-1731.
26. Hu CY, Xing Y, Cormier JN et al. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer 2013; 119:1900-1907.
27. Goldoni CA, Bonora K, Ciatto S et al. Misclassification of breast cancer as cause of death in a service screening area. Cancer Causes Control 2009; 20:533-538.